ApprovedFDA approval

Lumvoa (veligrotug-vvze)

Viridian Therapeutics (VRDN)

Marketer take

A second thyroid eye disease biologic after Tepezza, so ophthalmologists, oculoplastic surgeons and endocrinologists will see head-to-head differentiation messaging.

Sponsor company
Viridian Therapeutics (VRDN)
Indication
To treat thyroid eye disease
Therapeutic area
Ophthalmology, Immunology
Event
FDA approval
Date
Jun 26, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move